Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01/03/2024 – AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALS
26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024 – AB Science announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006